Partnership Improves Scalable Culture Solutions

Under a collaborative agreement, Sartorius Stedim Biotech (SSB) is to integrate Repligen’s ATF cell retention control technology into its large-scale single-use bioreactors providing a single control system for 50 L to 2,000 L bioreactors used in perfusion cell culture applications. SSB’s recently launched single-use mini bioreactor system will also be equipped with Repligen’s hollow fiber filter technology.

“Sartorius Stedim Biotech has continuously expanded its integrated upstream portfolio over the past years with a focus on robust and scalable, automated single-use solutions, optimised for high-cell-density applications. The collaboration with Repligen will result in easy-to-implement, high-performance and perfusion-ready bioreactors ranging from process development to commercial manufacturing scale,” commented Stefan Schlack, Head of Marketing at SSB.

Christine Gebski, Vice President of Product Management at Repligen, stated, “We are excited to partner with Sartorius Stedim Biotech, a global innovator in bioreactor technology. The integration of our market-leading XCell™ ATF control technology with SSB’s high-performance bioreactors offers a simplified perfusion-enabled bioreactor solution for end users to develop cell culture processes more quickly and implement perfusion more efficiently.”